USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS BY CARDIOLOGISTS SINCE THE RELEASE OF 2022 AHA/ACC/HFSA GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE

USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS BY CARDIOLOGISTS SINCE THE RELEASE OF 2022 AHA/ACC/HFSA GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE

Therapeutic Area: Heart Failure Background: Several studies have shown that most patients who are eligible for an Sodium-glucose Cotransporter-2 inhibitor (SGLT2i) are not receiving them and the proportion of prescriptions from cardiologists was very low (<2%) as of December 2020. Moreover, two S...

Full description

Bibliographic Details
Main Authors: Gowtham R. Grandhi, MD MPH, Rishav Adhikari, MD, Erfan Tasdighi, MD, Albert D. Osei, MD MPH, Michael Khorsandi, MD, Anurag Mehta, MD, Michael Blaha, MD MPH
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:American Journal of Preventive Cardiology
Online Access:http://www.sciencedirect.com/science/article/pii/S2666667723001137

Internet

http://www.sciencedirect.com/science/article/pii/S2666667723001137

Similar Items